Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Karola Rittner
Observed names:
K Rittner,
K. Rittner,
KAROLA RITTNER
Institution:
Transgene (France)
Observed institutions:
Transgene (France),
MRC Laboratory of Molecular Biology,
German Cancer Research Center,
Foundation for Research and Technology Hellas
ORCID:
0000-0002-6301-7198
Observed ORCID:
0000-0002-6301-7198
OpenAlex ID:
A5066332743
Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors
1998
·
Dirk Grimm
, Andrea Kern
, et al.
·
Human Gene Therapy
·
703
In Vitro and In Vivo Biology of Recombinant Adenovirus Vectors with E1, E1/E2A, or E1/E4 Deleted
1998
·
M. Lusky
, M. Christ
, et al.
·
Journal of Virology
·
276
PDF
New Basic Membrane-Destabilizing Peptides for Plasmid-Based Gene Delivery in Vitro and in Vivo
2002
·
Karola Rittner
, Annie Benavente
, et al.
·
Molecular Therapy
·
261
PDF
Up to 100-Fold Increase of Apparent Gene Expression in the Presence of Epstein-Barr Virus oriP Sequences and EBNA1: Implications of the Nuclear Import of Plasmids
1998
·
Françoise Längle-Rouault
, Volker Patzel
, et al.
·
Journal of Virology
·
129
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
2016
·
Patricia Kleinpeter
, Laetitia Fend
, et al.
·
OncoImmunology
·
102
Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1
1993
·
Matthias Homann
, Sergia Tzortzakaki
, et al.
·
Nucleic Acids Research
·
89
PDF
BERTMHC: improved MHC–peptide class II interaction prediction with transformer and multiple instance learning
2021
·
Jun Cheng
, Kaïdre Bendjama
, et al.
·
Bioinformatics
·
88
PDF
In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1
1993
·
Karola Rittner
, Christoph Burmester
, et al.
·
Nucleic Acids Research
·
79
The Human Immunodeficiency Virus Long Terminal Repeat Includes a Specialised Initiator Element which is Required for Tat-responsive Transcription
1995
·
Karola Rittner
, Mark J. Churcher
, et al.
·
Journal of Molecular Biology
·
71
Computer-Aided Search for Effective Antisense RNA Target Sequences of the Human Immunodeficiency Virus Type 1
1993
·
GEORG SCZAKIEL
, MATTHIAS HOMANN
, et al.
·
Antisense Research and Development
·
67
Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1
1991
·
Karola Rittner
, George Sczakiel
·
Nucleic Acids Research
·
61
Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis
1992
·
G Sczakiel
, M Oppenländer
, et al.
·
Journal of Virology
·
55
PDF
Adeno-associated virus type 2-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) replication: involvement of p78rep/p68rep and the HIV-1 long terminal repeat
1992
·
K. Rittner
, R. Heilbronn
, et al.
·
Journal of General Virology
·
48
Complementary Large Loops Determine the Rate of RNA Duplex Formation in Vitro in the Case of an Effective Antisense RNA Directed Against the Human Immunodeficiency Virus Type 1
1993
·
Matthias Homann
, Karola Rittner
, et al.
·
Journal of Molecular Biology
·
43
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
2017
·
Christelle Remy-Ziller
, Christine Thioudellet
, et al.
·
Human Vaccines & Immunotherapeutics
·
35
PDF
Adeno-associated virus type 2 rep gene-mediated inhibition of basal gene expression of human immunodeficiency virus type 1 involves its negative regulatory functions
1994
·
I Oelze
, K Rittner
, et al.
·
Journal of Virology
·
29
Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
2014
·
Laetitia Fend
, Tanja Gatard-Scheikl
, et al.
·
Cancer Immunology Research
·
22
Targeting of adenovirus vectors carrying a tumor cell-specific peptide: in vitro and in vivo studies
2007
·
K Rittner
, V Schreiber
, et al.
·
Cancer Gene Therapy
·
22
Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro
1997
·
K Rittner
, H Schultz
, et al.
·
Journal of Virology
·
22
TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy
2012
·
Laurent Amiset
, Laetitia Fend
, et al.
·
OncoImmunology
·
20
Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors
2016
·
Emmanuelle Schaedler
, Christelle Remy-Ziller
, et al.
·
Vaccine
·
17
Yeast Virus-Derived Stimulator of the Innate Immune System Augments the Efficacy of Virus Vector-Based Immunotherapy
2014
·
Marie-Christine Claudepierre
, Julie Hortelano
, et al.
·
Journal of Virology
·
16
PDF
Reduction in Replication of the Human Immunodeficiency Virus Type 1 in Human T Cell Lines by Polymerase III-Driven Transcription of Chimeric tRNA—Antisense RNA Genes
1994
·
UWE JUNKER
, KAROLA RITTNER
, et al.
·
Antisense Research and Development
·
13
NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response
2017
·
Anne Oberson
, Lorenzo Spagnuolo
, et al.
·
Oncotarget
·
6
PDF
Microinjection: A Technique to Study Inhibition of HIV-1 Replication Mediated by Antisense RNA and Parvovirus Genes
1993
·
Georg Sczakiel
, Ingo Oelze
, et al.
·
Springer eBooks
·
5
Show more works
View as search
Works count:
50
Citation count:
2,306
H-index:
20
I10-index:
23
Year
Topic
Type
